The development of treatments targeting KRAS mutations in solid cancers, including non-small cell lung cancer, is active. This year alone, seven companies were approved for nine related clinical trials. Amgen, which is leading the competition, is undergoing a domestic permit review.

According to the pharmaceutical industry on the 30th, there are a total of nine clinical trials related to KRAS that have been approved by the MFDS this year. The nine development stages were 5 cases in phase 1, 2 cases in phase 1/2, and 2 cases in phase 3.

KRAS was first discovered in 1982 as a genetic mutation in solid cancers such as non-small cell lung cancer and colon cancer. In lung adenocarcinoma, patie